FY26 Full Year Results Presentation

• Total revenue exceeded guidance, reaching NZ$104m
• Normalised EBITDA was NZ$11m, 174% of the guidance midpoint
• Myriad, the highest-growth product line, saw a 54% increase in sales

Aroa Biosurgery Ltd presented its FY26 full-year results, highlighting significant growth and profitability. The company exceeded its financial guidance, reporting total revenue of NZ$104 million, a 23% increase from FY25. Normalised EBITDA was NZ$11 million, surpassing the guidance midpoint by 174%. The Myriad product line, which saw a 54% sales increase, was the primary growth driver. Aroa also achieved a net cash flow of NZ$5 million, maintaining a debt-free position. The company's strategy focuses on three growth pillars: Myriad, Symphony, and OviTex, each targeting different market segments with strong clinical evidence and market potential.

Total revenue guidance: NZ$92-100m, FY26 result: NZ$104m; Normalised EBITDA guidance: NZ$5-8m, FY26 result: NZ$11m

Aroa Biosurgery Ltd expects continued growth driven by its high-margin product lines and strategic partnerships. The company plans to invest in sales capabilities and clinical evidence to capitalize on market opportunities, particularly in the complex wound and soft tissue reconstruction segments.